LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$89.04 USD
-0.82 (-0.91%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $89.05 +0.01 (0.01%) 7:40 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
LeMaitre Vascular (LMAT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$94.57 | $105.00 | $80.00 | 5.24% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for LeMaitre Vascular comes to $94.57. The forecasts range from a low of $80.00 to a high of $105.00. The average price target represents an increase of 5.24% from the last closing price of $89.86.
Analyst Price Targets (7 )
Broker Rating
LeMaitre Vascular currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, six are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/LMAT.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/20/2024 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
8/2/2024 | Not Identified | Not Identified | Hold | Hold |
8/2/2024 | Barrington Research | Michael J Petusky | Strong Buy | Strong Buy |
8/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/2/2024 | Lake Street Capital Markets | Brooks G O'Neil | Strong Buy | Strong Buy |
8/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/31/2024 | Roth Capital Partners | Jason Wittes | Not Available | Strong Buy |
2/6/2024 | KeyBanc Capital Markets | Brett Fishbin | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 8 |
Average Target Price | $94.57 |
LT Growth Rate | 20.50% |
Industry | Medical - Products |
Industry Rank by ABR | 98 of 253 |
Current Quarter EPS Est: | 0.44 |